Risperidone

Legal status and availability in the UK

In our online pharmacy, risperidone is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic risperidone information

• INN (international nonproprietary name): risperidone.
• Brand names available in the United Kingdom: Risperdal; Risperdal Consta; generic risperidone film-coated tablets (e.g. Risperidone 1 mg film-coated tablets).
• ATC code: N05AX08.
• Forms and strengths: film-coated tablets 0.25–6 mg; oral solution commonly 1 mg/mL; orally disintegrating tablets (ODT); long-acting IM depot (Risperdal Consta) 25 mg, 37.5 mg, 50 mg per injection.
• Manufacturers in the United Kingdom: not specified.
• Registration status in the United Kingdom: not specified.
• OTC / Rx classification: not specified.

Clinical effectiveness in the UK

How well does risperidone work in UK practice?

Risperidone remains a commonly prescribed antipsychotic for schizophrenia, manic episodes and selected behavioural problems.

It provides good symptomatic control of positive symptoms and acute agitation.

Switching to a depot such as Risperdal Consta can improve adherence and reduce relapse.

Common concerns include sedation, sexual dysfunction linked to raised prolactin and weight gain impacting long‑term adherence.

Shared decision‑making in UK practice balances relapse risk against metabolic and endocrine side‑effects, and routine monitoring is embedded in many pathways.

Indications and expanded uses

Patients often ask: what is risperidone officially approved to treat?

MHRA‑approved indications in the UK include schizophrenia, manic episodes of bipolar disorder and short‑term management of severe behavioural disturbance in Alzheimer’s dementia.

Licensed paediatric use covers specified conduct disorders in children.

Common off‑label uses in UK practice, used with governance and consent, include severe autism‑related aggression and adjunctive therapy for treatment‑resistant mood disorders.

Short‑term control of acute agitation in emergency settings is another pragmatic, locally governed use.

UK prescribing practice stresses documentation when using risperidone off‑label, informed consent and following local formularies and NICE guidance.

For dementia, guidance and audits emphasise non‑pharmacological approaches first and risperidone only when risk of harm exists and for the shortest duration.

• MHRA‑approved: schizophrenia; bipolar mania; short‑term behavioural disturbance in Alzheimer’s dementia; some paediatric conduct disorders.
• Common off‑label: autism‑related aggression; adjunct for resistant mood disorders; short‑term emergency agitation control.

Checklist for off‑label prescribing: document rationale, obtain informed consent, follow local formulary, record monitoring plan and review regularly.

Composition and brand landscape

Curious which formulations are most useful for everyday pharmacy practice?

The active ingredient is risperidone, an atypical antipsychotic with ATC code N05AX08.

UK brands include Risperdal and the long‑acting Risperdal Consta depot.

Numerous generics exist in the UK often labelled by strength, for example Risperidone 1 mg film‑coated tablets.

Commonly marketed forms and strengths include film‑coated tablets 0.25–6 mg, oral solution typically 1 mg/mL, ODT variants and Risperdal Consta injections of 25 mg, 37.5 mg and 50 mg.

NHS formularies typically list generic risperidone first‑line where clinically appropriate, with branded depot used as indicated by local policy.

Contraindications and special precautions

Who should be especially cautious when taking risperidone?

Absolute contraindication includes known hypersensitivity to risperidone or any excipients.

Caution is required for patients with Parkinson’s disease or Lewy body dementia due to sensitivity to antipsychotics.

Older adults with dementia carry increased stroke and mortality risk and risperidone should be used only sparingly with clear documentation.

Pregnant and breastfeeding women need a careful risk–benefit discussion with specialist input as advised in UK practice.

Children and adolescents require monitoring of growth, behaviour and prolactin where indicated and specialist paediatric psychiatry input is routine.

Patients with diabetes or metabolic syndrome should have baseline and ongoing metabolic monitoring.

Special precautions include risk of orthostatic hypotension on initiation, extrapyramidal symptoms and the rare but serious neuroleptic malignant syndrome.

• Checklist: confirm allergy status; review cardiac history; screen for diabetes; plan baseline weight, BMI and bloods.
• Monitoring triggers: new movement disorder, galactorrhoea or sexual dysfunction, unexplained fever or severe neutropenia.

Report serious adverse events to the MHRA Yellow Card scheme as part of ongoing pharmacovigilance.

Dosage guidelines

How is risperidone usually started and adjusted on an NHS prescription?

Typical adult oral initiation is low, for example 1–2 mg daily in divided doses or once daily, with gradual titration to effect.

Maintenance ranges commonly from 2–6 mg per day depending on response and tolerability.

UK tablet strengths of 0.25, 0.5, 1, 2, 3, 4 and 6 mg and an oral solution (commonly 1 mg/mL) permit flexible titration.

For Risperdal Consta depot, injection strengths are 25 mg, 37.5 mg and 50 mg every two weeks, and initial overlap with oral risperidone is required until therapeutic plasma levels are established.

Reduce dose in severe hepatic or renal impairment and consider slower titration in older adults or those with multiple comorbidities.

Paediatric dosing is weight‑based and condition‑specific and usually managed under specialist care.

Always follow specialist advice for complex patients and document dose changes in the GP record or shared care agreement.

Interactions overview

What common medicines or habits can change risperidone’s effects?

Concomitant CNS depressants such as benzodiazepines, opioids and alcohol increase sedation and respiratory depression risk and should be used cautiously.

Risperidone is metabolised partly via CYP2D6; strong inhibitors like fluoxetine and paroxetine can raise plasma levels and adverse‑effect risk.

CYP2D6 ultra‑metabolisers may have altered responses although routine genotyping is not standard in most NHS settings.

Antihypertensive drugs may have additive hypotensive effects and monitoring of blood pressure is advised when starting or increasing doses.

Drugs that prolong the QT interval warrant caution and ECG assessment if additional risk factors are present.

Dietary interactions are limited; alcohol should be minimised as it potentiates sedation and impairs judgement.

Comparable medicines and prescribing preferences

How do prescribers choose between risperidone and alternatives?

Common alternatives on NHS formularies include olanzapine, quetiapine, aripiprazole, amisulpride and haloperidol for selected cases.

Choice factors include efficacy for positive and negative symptoms, side‑effect profiles and past individual response.

Olanzapine tends to have higher metabolic risk, aripiprazole lower prolactin effect and quetiapine more sedation, factors that guide choice in clinic.

Depot alternatives include paliperidone palmitate and aripiprazole LAI, with paliperidone being the active metabolite of risperidone and having different licensing nuances.

NHS preference usually follows local formularies and shared care agreements, and switching requires cross‑tapering, baseline ECG and metabolic checks.

• Pros of risperidone: well‑established efficacy, multiple formulations including depot.
• Cons of risperidone: higher prolactin risk, some weight gain, caution in dementia.

Switching checklist: confirm indication, plan cross‑taper, obtain baseline metabolic and ECG data, document consent and arrange follow‑up.

FAQ

Will risperidone make me gain weight?

Weight gain is a recognised side‑effect and NHS advice includes baseline and ongoing weight and BMI monitoring plus diet and exercise support.

How long before risperidone works?

Some improvement in agitation may be seen within days, but full antipsychotic effect is typically assessed over 2–6 weeks with dose adjustments as needed.

Can I drink alcohol while on risperidone?

Alcohol increases sedation and should be avoided or minimised; discuss alcohol use with the prescriber or pharmacist.

What if I want to stop?

Do not stop abruptly; arrange a supervised taper with your prescriber to reduce relapse and withdrawal risks and request specialist review where appropriate.

For concerns such as sexual side‑effects or raised prolactin, ask your GP or pharmacist for blood tests and referral to specialist care if required.

Signposts: contact NHS 111 for urgent queries, your local mental health team for follow‑up and your community pharmacist for medication counselling.

Guidelines for proper use

What should a pharmacist tell someone starting risperidone?

Confirm the indication and formulation and explain expected benefits and a realistic timescale for improvement.

Review common side‑effects such as sedation, weight gain and prolactin‑related effects and advise on when to seek urgent review for serious symptoms.

Advise on driving and operating machinery, and warn that alcohol potentiates central nervous system depression.

Outline the monitoring schedule: baseline weight, BMI, fasting glucose, lipids and blood pressure, with prolactin testing if clinically indicated.

For depot therapy explain the injection schedule, clinic attendance requirements, need for oral overlap and injection‑site care.

Use NHS patient leaflets, the NHS App and the medicines summary on NHS login to provide written information and reminders.

• Counselling checklist: indication, dosing, side‑effects, monitoring, driving advice, follow‑up plan.
• Reporting: encourage Yellow Card reporting of serious adverse reactions.

Where patients prefer, provide a written take‑home summary and signpost local support groups and community mental health services.

Delivery across the United Kingdom